Autolus Therapeutics (AUTL) Receivables - Net (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Receivables - Net for 9 consecutive years, with $24.0 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Net rose 160060.0% year-over-year to $24.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.0 million (up 160060.0% YoY) and the FY2025 annual result came in at $24.0 million, up 160060.0% from the prior year.
• Receivables - Net eased to $24.0 million in Q4 2025 per AUTL's latest filing, from $32.6 million in the prior quarter.
• Over the last five years, Receivables - Net for AUTL reached as high as $32.6 million in Q3 2025 and fell as low as $15000.0 in Q4 2024.
• A 5-year average of $6.0 million and a median of $293000.0 in 2022 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net sank 92.1% — and 2025, when it surged 160060.0%.
• Year by year, Receivables - Net stood at $384000.0 in 2021, then slumped by 68.49% to $121000.0 in 2022, then fell by 9.92% to $109000.0 in 2023, then slumped by 86.24% to $15000.0 in 2024, then jumped by 160060.0% to $24.0 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $24.0 million, $32.6 million, and $26.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.